Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.

PLoS One · 2014 · PMC4267740 · PMID 25513815

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

marginally significantp = 0.07so close (0.05 < p ≤ 0.1)

Marginally significant effects of the interaction was also reported for two additional combinations: Sch-58261+ Merck 22 (p = 0.07) and Tozadenant + Radiprodil (p = 0.06).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.